Insight journal, Insight journal - Company

PDL Biopharma: Capitalizing on the humanization of monoclonal antibodies

Posted on 27 May 2014

Tags: , , ,

PDL Biopharma based in Nevada manages patents associated with its humanized monoclonal antibodies technology.

PDL Biopharma formerly known just as Protein Design Labs was the company to humanize monoclonal antibodies, which has opened the doors for and is behind the development of many successful autoimmune disease therapies worldwide. Due to the pure phenomenal personal success of its technology, the company now simply manages intellectual property assets and provides funding using the incoming royalty payments from the many pharmaceutical and biotechnology companies who licence its antibody technology out.

PDL Biopharma’s technology is used by blockbuster products such as cancer therapy Avastin®, macular degeneration product Lucentis®, multiple sclerosis product Tysabri® and rheumatoid arthritis therapy Actemra® amongst many others.

The significant royalty payments from these products has allowed the company to re-focus its whole company  and offer funding to pharma and biotech companies with aspiring assets and technologies. PDL provides non-dilutive growth capital and financing options to late stage companies. It also monetizes royalty streams to companies, academic institutions and investors. PDL has sold its existing assets and R&D divisions to focus only on financing.

Blockbuster antibody technology

Monoclonal antibodies are known as ‘targeted therapy’ that treats diseased cells only. Traditionally monoclonal antibodies were made from mouse cells then implanted into the body to target and destroy specific antigens attached to cancer cells. However as mouse cells are seen as ‘foreign’ in the body, an immune system would be built up against them eventually and they would only be effective the first time they were used before they became destroyed themselves.

Protein Design Laboratories as it was then known created a technology that began to incorporate more human components into the mouse antibodies, hence making them humanized. These new human effective antibodies were then used to target some of the diseases threatening today’s society such as oncology, multiple sclerosis and rheumatoid arthritis.

Partnering with PDL

First and foremost PDL has been involved in a number of different licensing agreements, to license out its successful technology. The technology spoke for itself in this situation and regardless of the team and partnering strategy behind PDL the licensing agreements were signed swiftly and in high numbers. PDL has licensing agreements with Roche, Biogen Idec and Chugai.

Following on from this PDL is now involved in different kinds of deals; financing deals such as royalty monetizing, growth capital and debt financings. The company supports medical device, pharma, academic institutions all developing and commercializing technologies and products.

PDL prides itself as being able to analyze and execute financings quickly using its expertise in clinical, medical, pharma and biotech operations. PDL offers flexibility in financings and conducts all transactions with speed after initial assessments and deal terms have been set out. 

Partnering outreach

PDL Biopharma is often present at a large number of partnering and financing events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.

Other events with PDL Biopharma presence include but are not limited to:

  • BIO International Convention and Business Forum
  • BioEurope / BioEurope Spring

For a full list of forthcoming partnering events where you could meet with PDL Biopharma in person visit Current Partnering’s Event calendar.   

Contacting PDL Biopharma for partnering

PDL Biopharma can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:  

Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.

See Current Partnering’s event calendar for details of forthcoming events.  

Direct contact: there are several sources of direct contact with PDL Biopharma Pharmaceuticals’ business development team

Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity or proposal.

Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/financing/technology area being targeted and get in touch. This page on the PDL Biopharma  website has details for contacting PDL Biopharma.

LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.

Many of PDL Biopharma business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit PDL Biopharma Linkedin page

Raveena Bhambra  

*www.pdl.com

Source: Current Agreements, 2014

Our report provides more detailed insight into the type of financial investment entered into by PDL Biopharma. See: Partnering Agreements with PDL Biopharma 2009-2014

More

Summary profile for PDL Biopharma

Partnering activity for PDL Biopharma

No M&A deals recorded for PDL Biopharma since 2009 

 

Available reports from Current Partnering

Report: Partnering Agreements with PDL Biopharma 2009-2014

Report: Partnering Deals and Alliances with Big Biotech

 

Available resources for deal coverage for PDL Biopharma

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on PDL Biopharma  company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Finding Biopharma Licensing and Collaboration Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply